We are a biopharmaceutical company focused on developing a portfolio of internally discovered product candidates that utilize the body's natural nutrient transporter mechanisms to improve the therapeutic benefits of drugs.
This icon indicates a link to an external site.
June 30, 2009
XenoPort Reports Positive Results from a Phase 2 Trial of Arbaclofen Placarbil in Spinal Cord Injury Patients with Spasticity
June 12, 2009
XenoPort to Present at the Piper Jaffray Fourth Annual Europe Conference Printer Friendly Version
Tuesday, June 30, 2009 9:00 a.m. ET
XenoPort Reports Positive Results from a Phase 2 Trial of Arbaclofen Placarbil in Spinal Cord Injury Patients with Spasticity
Tuesday, June 23, 2009 12:00 Noon UKT
XenoPort, Inc. at Piper Jaffray Europe Conference
Legal Message | Privacy | © 2008. All rights reserved.